H.C. Wainwright lowered the firm’s price target on Prothena (PRTA) to $30 from $48 and keeps a Buy rating on the shares. The firm dropped the stock’s valuation multiples to better align with current investor sentiment, elevated cost of capital, and reduced appetite for early-stage clinical risk.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTA:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue